The FDA guidance document on listeria control is intended for food manufacturers who are making RTE products and are subject to 21 CFR 117.
Listeria monocytogenes is an environmental pathogen that can contaminate foods and cause a mild non-invasive illness called listerial gastroenteritis or a severe invasive illness called listeriosis. Listeriosis is characterised by a relatively high mortality rate compared to illnesses caused by most other foodborne pathogens (20% compared to less than 1% for salmonella or E.Coli 0157). Persons who are at greatest risk of experiencing Listeriosis due to consumption of food contaminated by L. Monocytegenes are pregnant women and their foetuses, the elderly and persons with weakened immune systems. Foods that have caused outbreaks are typically contaminated from the environment during manufacturing, processing or packaging.
Although temperatures below freezing prevent the growth of L. mono it can multiply slowly at refrigeration temperatures (will grow at -0.4° C). As a result refrigeration is less effective as a control measure for L. mono than other food borne pathogens.
Listeriosis is largely associated with RTE foods. It is well established that the foods which pose the greatest risk of foodborne Listeriosis are those ready to eat foods that have intrinsic characteristics such as pH & Aw that support growth. To control L mono an FBO must first understand the bacteria itself and then how to control the environment that it can be found in. The FDA guidance document is very well designed to logically address the L. mono challenge.
Within Europe, the recent amendments to 2073/2005 – 2024/2895 (Commission Regulation (EU) 2024/2895 of 20 November 2024 amending Regulation (EC) No 2073/2005 as regards Listeria monocytogenes) comes into effect on July 1st 2026. This amendment introduces a change to the criterion for Listeria monocytogenes in RTE foods. The new EU rules will focus on RTE foods that support the growth of L.mono.